半量替罗非班对急诊冠状动脉介入治疗术后TIMI血流3级患者的疗效及安全性 Efficacy and Safety of Half-Dose Tirofiban for Acute ST-Elevation Myocardial Infarction Patients with TIMI 3 Flow After Percutaneous Coronary Intervention
Manoukian SV,Feit F,Mehran R,et al.Impact of major bleeding on 30day mortality and clinical outcomes in patients with acute coronary syndromes:an analysis from the ACUITY trial[J].J Am Coll Cardiol,2007,49(12):1 362-1 368.
[2]
Rao SV,O’Grady K,Pieper KS,et al.A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes[J].J Am Coll Cardiol,2006,47(4):809-816.
[3]
Rao SV,O'Grady K,Pieper KS,et al.Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes[J].Am J Cardiol,2005,96(9):1 200-1 206.
[4]
Hamm CW,Bassand JP,Agewall S,et al.ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation:The Task Force for the management of acute coronary syndromes(ACS)in patients presenting without persistent ST-segment elevation of the European Society of Cardiology(ESC)[J].Eur Heart J,2011,32(23):2 999-3 054.
[5]
Topcu S,Karal H,Kaya A,et al.The Safety and Efficacy of 12 Versus 24 Hours of Tirofiban Infusion in Patients Undergoing Primary Percutaneous Coronary Intervention[J].Clin Appl Thromb Hemost,2015,21(8):783-789.
[6]
Thiele H,Schindler K,Friedenberger J,et al.Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention:the randomized Leipzig immediate percutaneous coronaryintervention abciximabⅣversus IC in STelevation myocardial infarction trial[J].Circulation,2008,118(1):49-57.
[7]
Yang X,Alexander KP,Chen AY,et al.The implications of blood transfusions for patients with non-STsegment elevation acute coronary syndromes:results from the CRUSADE National Quality Improvement Initiative[J].J Am Coll Cardiol,2005,46(8):1 490-1 495.
[8]
Fokkema ML,Vlaar PJ,Svilaas T,et al.Incidence and clinical consequences of distal embolization on the coronary angiogram after percutaneous coronary intervention for ST-elevation myocardial infarction[J].Eur Heart J,2009,30(8):908-915.
[9]
Ottani F,La Vecchia L,De Vita M,et al.comparison by meta-analysis of eptifibatide and tirofiban to abciximab in patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention[J].Am J Cardiol,2010,106(2):167-174.
[10]
Valgimigli M,Biondi-Zoccai G,Tebaldi M,et al.Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention:a meta-analysis of randomized trials[J].Eur Heart J,2010,31(1):35-49.
[11]
Sabatine MS,Morrow DA,Giugliano RP,et al.Association of hemoglobin levels with clinical outcomes in acute coronary syndromes[J].Circulation,2005,111(16):2 042-2 049.
[12]
Eikelboom JW,Mehta SR,Anand SS,et al.Adverse impact of bleeding on prognosis in patients with acute coronary syndromes[J].Circulation 2006,114(8):774-782.
